Key clinical point: An assay using targeted methylation sequencing of plasma cell-free DNA had high accuracy in detecting diverse GI cancers.
Major finding: Overall sensitivity was 82% in the training set and 81% in the validation set at specificity exceeding 99%; overall accuracy for defining GI tissue of origin was 91% and 89%, respectively.
Study details: A prospective, multicenter case-control study including 2,185 patients with cancer (447 with GI cancer) and 2,131 individuals without cancer (Circulating Cell-free Genome Atlas study).
Disclosures: Dr. Wolpin disclosed having a relationship with various pharmaceutical companies, including GRAIL, which funded the study. Dr. Fisher disclosed relationships with numerous pharmaceutical companies and that an immediate family member has stock in Seattle Genetics.
Wolpin BM et al. 2020 GI Symposium, Abstract 283.